Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3169-3176

  Defronzo, Ralph A ^a   Hompesch, Marcus ^b   Kasichayanula, Sreeneeranj ^c   Liu, Xiaoni ^c   Hong, Ying ^c   Pfister, Marc ^c   Morrow, Linda A ^b   Leslie, Bruce R ^c   Boulton, David W ^c   Ching, Agatha ^c   Lacreta, Frank P ^c   Griffen, Steven C ^c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Profil Institute for Clinical Research   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DAPAGLIFLOZIN; GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; METFORMIN; OCTREOTIDE; RECOMBINANT HUMAN INSULIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; KIDNEY TUBULE ABSORPTION; MALE; METABOLIC PARAMETERS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL SYSTEM PARAMETERS;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 84891865819     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0387     Document Type: Article

References (26)

1. Valtin H. Renal Function: Mechanism Preserving Fluid and Solute Balance in Health. Boston, Little, Brown and Company, 1983
2. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22:104-112
3. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-794
4. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-531
5. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30:125-129
6. Mogensen CE. Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 1971;28:183-193
7. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodiumglucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320:323-330
8. Noonan WT, Shapiro VM, Banks RO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocininduced diabetic rats. Life Sci 2001;68: 2967-2977
9. Marks J, Carvou NJC, Debnam ES, Srai SK,Unwin RJ.Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003;553:137-145
10. Freitas HS, Anhě GF,Melo KF, et al. Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor- 1alpha expression and activity. Endocrinology 2008;149:717-724
11. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-3434
12. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519
13. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657
14. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-516
15. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-2233
16. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care 2010;33:2217-2224
17. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-1662
18. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-526
19. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672
20. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney functiondmeasured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
22. Sterner G, Frennby B, Mansson S, Nyman U, Van Westen D, Almén T. Determining 'true' glomerular filtration rate in healthy adults using infusion of inulin and comparing it with values obtained using other clearance techniques or prediction equations. Scand J Urol Nephrol 2008;42:278-285
23. Heinemann L, Ampudia-Blasco FJ. Glucose clamps with the Biostator: a critical reappraisal. Horm Metab Res 1994;26: 579-583
24. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
25. Liu JJ, Lee TW, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61:2199-2204
26. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2013;304:E117-E130